Shikari® (Q-ATI) Anti-Infliximab ELISA

Enzyme immunoassay for the qualitative determination of antibodies to Infliximab (Remicade®) in serum and plasma.

This kit has been especially developed for the qualitative antibodies to infliximab in serum and plasma samples

Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. The Matriks Biotek shikari® Antibody to Infliximab ELISA Kit can be efficiently used for monitoring anti-Infliximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Infliximab antibodies.

All SHIKARI® ELISA kits are suitable for biosimilar work.